Andy Pasternak - Jan 17, 2023 Form 4 Insider Report for Horizon Therapeutics Public Ltd Co (HZNP)

Role: EVP, Chief Strategy Officer
Signature: /s/ Patrick McIlvenny, Attorney-in-Fact
Stock symbol: HZNP
Transactions as of: Jan 17, 2023
Transactions value $: -$3,066,323
Form type: 4
Date filed: 1/18/2023, 03:19 PM
Previous filing: Jan 6, 2023
Next filing: Oct 6, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	HZNP	Ordinary Shares	Sale	-$3.07M	-27.1K	-32.5%	$113.03	56.3K	Jan 17, 2023	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2022.
F2	The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.00 to $113.0750 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Content

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2022.

The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.00 to $113.0750 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.